Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09KTS
|
||||
Former ID |
DNCL002550
|
||||
Drug Name |
Ibrutinib
|
||||
Synonyms |
PCI-32765; Ibrutinib (BTK inhibitor)
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Chronic lymphocytic leukaemia; Refractory or relapsed mantle cell lymphoma [ICD9: 200.4; ICD10:C91, C85.7] | Approved | [1], [2], [3] | ||
Company |
Janssen Biotech; Pharmacyclics
|
||||
Structure |
Download2D MOL |
||||
Formula |
C25H24N6O2
|
||||
InChI |
InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
|
||||
InChIKey |
XYFPWWZEPKGCCK-GOSISDBHSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
49837088, 57132050, 123051065, 124898784, 124898785, 136940589, 136961336, 137472671, 152258295, 160647134, 162202692, 163312254, 163679284, 164045821, 164193915, 165245631, 171572071, 172919350, 174007139, 175267389, 176250273, 178103494, 184611713, 184816969, 189025882, 198993428, 215784879, 223375297, 223485070, 223600477, 223685684, 223704724, 224184328, 226558356, 242585660, 247523488, 249736825, 251971042, 252088605, 252110183, 252160516, 252215999, 252451849
|
||||
Drug Resistance Mutation (DRM) | |||||
DRM | DRM Info | ||||
Target and Pathway | |||||
Target(s) | Tyrosine-protein kinase BTK | Target Info | Inhibitor | [4] | |
KEGG Pathway | NF-kappa B signaling pathway | ||||
Osteoclast differentiation | |||||
Platelet activation | |||||
B cell receptor signaling pathway | |||||
Fc epsilon RI signaling pathway | |||||
Primary immunodeficiency | |||||
PANTHER Pathway | B cell activation | ||||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | ||||
BCR signaling pathway | |||||
FAS (CD95) signaling pathway | |||||
Class I PI3K signaling events | |||||
EPO signaling pathway | |||||
PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
Reactome | MyD88:Mal cascade initiated on plasma membrane | ||||
Regulation of actin dynamics for phagocytic cup formation | |||||
DAP12 signaling | |||||
FCERI mediated Ca+2 mobilization | |||||
MyD88 deficiency (TLR2/4) | |||||
IRAK4 deficiency (TLR2/4) | |||||
RHO GTPases Activate WASPs and WAVEs | |||||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
WikiPathways | Kit receptor signaling pathway | ||||
MyD88:Mal cascade initiated on plasma membrane | |||||
Signaling by the B Cell Receptor (BCR) | |||||
DAP12 interactions | |||||
B Cell Receptor Signaling Pathway | |||||
TSLP Signaling Pathway | |||||
Regulation of toll-like receptor signaling pathway | |||||
IL-5 Signaling Pathway | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT01833039) An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma. U.S. National Institutes of Health. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6912). | ||||
REF 3 | Janssen's IMBRUVICA (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenstrom's Macroglobulinemia. Janssen-Cilag International NV (Janssen). Jul 10, 2015. | ||||
REF 4 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.